Stocksigma LogoStocksigma Logo

Tavexia Lifecare to Acquire 60% Stake in Meyonex Pharmaceuticals for ₹67.19 Crore

The board of Tavexia Lifecare approved the acquisition of a 60% controlling stake in unlisted Meyonex Pharmaceuticals Limited on 7th Oct'26

Tavexia Lifecare to Acquire 60% Stake in Meyonex Pharmaceuticals for ₹67.19 Crore

Sattva Sukun Lifecare Ltd · Others (Uncategorized) · 08 Oct 2026, 4:16 am

Tavexia Lifecare to Acquire 60% Stake in Meyonex Pharmaceuticals for ₹67.19 Crore The board of Tavexia Lifecare approved the acquisition of a 60% controlling stake in unlisted Meyonex Pharmaceuticals Limited on 7th Oct'26. The transaction involves subscribing to 2,09,97,180 fresh equity shares at an issue price of ₹32 per share, totaling a cash consideration of ₹67.19 crore. To finance the acquisition, the board granted in-principle approval to raise funds via equity, warrants, or debt on a preferential or rights issue basis, subject to shareholder and regulatory approvals. Meyonex reported FY25 turnover of ₹10.79 crore.

Original exchange filing (PDF)

More announcements from Sattva Sukun Lifecare Ltd

All Sattva Sukun Lifecare Ltd announcements